UBS Group AG Cuts Stake in CG Oncology, Inc. $CGON

Key Points

• UBS Group AG trimmed its Q4 holding in CG Oncology by 9.5%, selling 202,524 shares and leaving it with 1,923,746 shares (about 2.38%) worth roughly $79.9 million.
• Analysts are broadly positive—11 Buys, 1 Hold and 1 Sell—resulting in a consensus rating of Moderate Buy and an average price target of $79.55, with several firms recently raising targets.
• Director James Mulay sold 15,600 shares at an average $73.01 (≈$1.14M), halving his stake; the stock trades near its 52‑week high (range $21.00–$73.56) and the company has a market cap of $5.83 billion.

UBS Group AG lessened its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 9.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,923,746 shares of the company's stock after selling 202,524 shares during the period. UBS Group AG owned approximately 2.38% of CG Oncology worth $79,874,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology in the fourth quarter valued at $27,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology during the 3rd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in CG Oncology by 33.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company's stock worth $163,000 after purchasing an additional 972 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in CG Oncology in the 3rd quarter valued at about $211,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in CG Oncology in the 3rd quarter valued at about $208,000. Institutional investors and hedge funds own 26.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a research note on Friday, January 9th. JPMorgan Chase & Co. boosted their price target on shares of CG Oncology from $65.00 to $91.00 and gave the stock an "overweight" rating in a report on Friday, April 17th. Royal Bank Of Canada increased their price objective on shares of CG Oncology from $73.00 to $79.00 and gave the company an "outperform" rating in a research report on Monday, April 27th. The Goldman Sachs Group restated a "buy" rating and issued a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Finally, HC Wainwright lifted their price objective on shares of CG Oncology from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $79.55.

Insider Activity at CG Oncology

In related news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director directly owned 15,600 shares in the company, valued at $1,138,956. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.80% of the stock is owned by company insiders.

CG Oncology Price Performance

Shares of CGON opened at $66.27 on Monday. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of -32.01 and a beta of 0.41. CG Oncology, Inc. has a 52-week low of $21.00 and a 52-week high of $73.56. The stock has a 50 day moving average price of $65.06 and a 200 day moving average price of $52.32.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. On average, equities analysts anticipate that CG Oncology, Inc. will post -2.56 EPS for the current fiscal year.

CG Oncology Profile

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc. (NASDAQ:CGON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.